CJC-1295 (no DAC) + Ipamorelin

Fat LossGHRH + GHS combinationExperimental

Also known as: CJC / Ipamorelin blend, GHRH + GHS stack

CJC-1295 (no DAC) + Ipamorelin, also called CJC / Ipamorelin blend or GHRH + GHS stack, is a research peptide in the GHRH/GHRP class. This combination pairs a GHRH receptor agonist with a ghrelin receptor agonist, which is pharmacologically distinct from combining two agents of the same class.

Calculate Dose

For research use only.

Key Facts

CAS
N/A (blend)
Molecular Weight (MW)
Varies
Half-life
CJC: ~30 min; Ipa: ~2 hours
FDA status
Not Approved
Evidence level
Insufficient Evidence
Human dose established
No
Administration Route
Not established in humans
Frequency
Not established in humans
Last updated
Nov 7, 2026
Reviewed
Nov 7, 2026
Targets
GHRH receptorGHSR (ghrelin receptor)

Vendor price snapshot

Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Oct 2026 and Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.

Vendors listing this peptide
39
Listed offers
76
Median price per mg (peptide vials)
$5.68/mg
Typical $4.50–$7.00/mg

By form

Each form is priced on its own: a price per mg doesn't make a spray or a capsule equivalent to a vial.

Open calculator · Compare vendors

Research summary

Research blend combining a GHRH analog (usually Mod GRF / CJC no DAC) with ipamorelin to stimulate GH via two receptor classes. Not FDA-approved. Both components are WADA S2.

Research evidence

  • Regulatory review (FDA label)None in reviewed sources
  • Controlled human trialsNone in reviewed sources
  • Early or uncontrolled human studiesNone in reviewed sources
  • Lab & animal studiesNone in reviewed sources
How it works

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

Peptide Library's CJC-1295 (no DAC) + Ipamorelin profile summarises 2 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

CJC-1295 (no DAC) + Ipamorelin dosage: no established human dose

The CJC-1295 (no DAC) and ipamorelin blend has no established human dosage. No human study has tested the two together. CJC-1295 without DAC has no human study of its own: the published human data is for the longer-acting DAC form, a different molecule. Ipamorelin has been given to people only intravenously, in a pharmacokinetic study and a post-surgery trial.

Insufficient Evidence

No established human dosage.

Human clinical evidence: None identified.

Preclinical research: The blend pairs a GHRH analogue (CJC-1295 without DAC, also sold as Mod GRF(1-29)) with a ghrelin-receptor agonist (ipamorelin). No study of the two given together was found in PubMed or ClinicalTrials.gov. CJC-1295 without DAC has no indexed human study at all, and ipamorelin's human data is intravenous only, so neither component supplies a dose for this blend.

Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.

Dosage evidence summary for CJC-1295 (no DAC) + Ipamorelin
Human dosing establishedNo
RouteNot established in humans
Evidence levelInsufficient Evidence
Last reviewed2026-11-07

Preclinical and analog research

Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.

Research-reported dosing for CJC-1295 (no DAC) + Ipamorelin, one row per studied regimen
Study / contextPopulationDoseRouteFrequencyDurationOutcome studiedSource
Component (analog evidence) — CJC-1295 with DAC, a different molecule from the no-DAC form in this blend (Teichman et al., 2006)Clinical trial · Two randomised placebo-controlled ascending-dose trials of the DAC analogue, not the no-DAC componentStudied an analog, not CJC-1295 (no DAC) + Ipamorelin itselfHealthy adults aged 21–61One of four ascending single doses, or two or three weekly or biweekly doses; the authors describe 30 or 60 mcg/kg as relatively well toleratedSubcutaneousSingle dose, or weekly or biweekly28 and 49 daysGrowth hormone rose 2- to 10-fold for 6 days or more and IGF-1 1.5- to 3-fold for 9–11 days after one injection; estimated half-life 5.8–8.1 daysTeichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006.
Component (analog evidence) — ipamorelin: human pharmacokinetic study (Gobburu et al., 1999)Clinical trial · Human dose-escalation PK/PD study of one component aloneStudied an analog, not CJC-1295 (no DAC) + Ipamorelin itselfHealthy male volunteers, 8 per dose level4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg of ipamorelin alone (dose escalation)Intravenous infusion over 15 minutesSingle dose per levelSingle 15-minute infusionDose-proportional pharmacokinetics, terminal half-life about 2 hours, and a single episode of growth hormone release at every doseGobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999.
Component (analog evidence) — ipamorelin: phase 2 trial in post-operative ileus (Beck et al., 2014; NCT00672074)Clinical trial · Phase 2 double-blind randomised placebo-controlled trial of one component aloneStudied an analog, not CJC-1295 (no DAC) + Ipamorelin itselfAdults after small or large bowel resection (117 enrolled, 114 analysed)0.03 mg/kg of ipamorelin aloneIntravenous infusionTwice dailyPostoperative day 1 to day 7, or until dischargeNo significant difference from placebo in time to first tolerated solid meal (p = 0.15)Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus. Int J Colorectal Dis. 2014.

Where sources disagree

  • A blend's amount of CJC-1295 or ipamorelin is not a dose that was studied for that compound. See the CJC-1295 (no DAC) and Ipamorelin profiles for what each component's evidence shows.
  • The CJC-1295 human study used the DAC form, which lasts days rather than minutes. Its doses and dosing interval do not carry over to the no-DAC form sold in this blend.
  • Shop listings sell the blend as one total amount, most often 10 mg or 20 mg, and the split between the two components (usually equal) is set by the seller.

Reconstitution

Common research vial sizes: 10 mg, 20 mg.

Reconstitution arithmetic for CJC-1295 (no DAC) + Ipamorelin
VialBacteriostatic waterConcentrationPer 0.01 mL
10 mg2 mL5 mg/mL of total blend50 mcg of total blend per 0.01 mL
20 mg2 mL10 mg/mL of total blend100 mcg of total blend per 0.01 mL

These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.

Calculate reconstitution & dose →

Handling & administration

Reconstitution Guide
3 mL BAC for 6mg/12mg blend
Injection Sites
Abdomen
Concentration Example
18 mg / 3 mL = 6 mg/mL
Timing Notes
Bedtime/AM
Expected Onset
1-2 weeks

How to reconstitute CJC-1295 (no DAC) + Ipamorelin

  1. Check the vial size and diluent volume. The profile example for CJC-1295 (no DAC) + Ipamorelin is: 3 mL BAC for 6mg/12mg blend.
  2. Swab both vial stoppers and draw the bacteriostatic water into a sterile syringe.
  3. Add the water slowly down the inside wall of the peptide vial so it does not jet onto the powder, then swirl gently until the solution is clear. Do not shake.
  4. Record the resulting concentration: 18 mg / 3 mL = 6 mg/mL.
  5. Label the vial with the date and concentration, refrigerate it (see Storage & stability below), and use the calculator preset to convert a dose in mcg into syringe units.

Open the peptide calculator with the CJC-1295 (no DAC) + Ipamorelin preset →

Sequence & molecular data

Sequence and molecular data for CJC-1295 (no DAC) + Ipamorelin
Amino acid sequenceCJC: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2; Ipa: Aib-His-D-2-Nal-D-Phe-Lys-NH2
Molecular formulaVaries (blend)
Molecular weightVaries
CAS numberN/A (blend)
Half-lifeCJC: ~30 min; Ipa: ~2 hours
AppearanceWhite lyophilized powder
FormulationLyophilized Powder

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

This combination pairs a GHRH receptor agonist with a ghrelin receptor agonist, which is pharmacologically distinct from combining two agents of the same class. CJC-1295 without DAC binds the GHRH receptor on somatotrophs and raises cyclic AMP, increasing growth hormone synthesis and release, while ipamorelin binds growth hormone secretagogue receptor 1a and additionally reduces hypothalamic somatostatin tone. Because the two receptors converge on growth hormone release through separate signalling routes and somatostatin inhibition is relieved at the same time, the combined effect reported in experimental settings exceeds the sum of either alone. No controlled human trials of this specific blend have been published.

Origin

Combination of two synthetic GH secretagogues.

Targets

GHRH receptorGHSR (ghrelin receptor)

Regulatory & research status

CJC-1295 (no DAC) + Ipamorelin is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

Regulatory and research status for CJC-1295 (no DAC) + Ipamorelin
FDA statusNot Approved
AvailabilityResearch-Only
WADA (sport)Banned in Sport
Library classificationResearch-Only

How FDA approval, compounding and research-only status differ

Benefits

GH optimizationRecoveryFat lossSleep quality

CJC-1295 (no DAC) + Ipamorelin side effects

CJC-1295 (no DAC) + Ipamorelin has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.

Side Effects

  • Flushing
  • Headache
  • Water retention

Contraindications

  • Cancer history

Stacking

Common stacking partners

Combinations that include CJC-1295 (no DAC) + Ipamorelin, with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.

Storage & stability

Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.

Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.

Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.

Read the full guide: how to store peptides before and after reconstitution →

Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.

CJC-1295 (no DAC) + Ipamorelin: frequently asked questions

What is CJC-1295 (no DAC) + Ipamorelin?

Research blend combining a GHRH analog (usually Mod GRF / CJC no DAC) with ipamorelin to stimulate GH via two receptor classes. Not FDA-approved. Both components are WADA S2.

How does CJC-1295 (no DAC) + Ipamorelin work?

This combination pairs a GHRH receptor agonist with a ghrelin receptor agonist, which is pharmacologically distinct from combining two agents of the same class. CJC-1295 without DAC binds the GHRH receptor on somatotrophs and raises cyclic AMP, increasing growth hormone synthesis and release, while ipamorelin binds growth hormone secretagogue receptor 1a and additionally reduces hypothalamic somatostatin tone.

Is CJC-1295 (no DAC) + Ipamorelin FDA approved?

No. CJC-1295 (no DAC) + Ipamorelin is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

What is the half-life of CJC-1295 (no DAC) + Ipamorelin?

Reported half-life for CJC-1295 (no DAC) + Ipamorelin is CJC: ~30 min; Ipa: ~2 hours. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

What is the amino acid sequence of CJC-1295 (no DAC) + Ipamorelin?

CJC-1295 (no DAC) + Ipamorelin has the sequence CJC: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2; Ipa: Aib-His-D-2-Nal-D-Phe-Lys-NH2, giving a chain of 36 amino acids. Its molecular formula is Varies (blend).

Is CJC-1295 (no DAC) + Ipamorelin banned in sport?

CJC-1295 (no DAC) + Ipamorelin is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

References

Related research, comparisons & guides

Related peptides

Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 3

This CJC-1295 (no DAC) + Ipamorelin profile is compiled from published literature (2 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error

Track CJC-1295 (no DAC) + Ipamorelin research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →